Allarity Therapeutics, Inc. ALLR
Regular-session close
After hours · Nov 16, 6:03 PM ET
- YTD
- -18.96%
- 1 year
- -25.83%
- Market cap
- 13.93M
- EPS (ttm)
- -0.79
- Shares out
- 4.43M
- Forward P/E
- -0.02
- YTD return
- -18.96%
- 1-year return
- -25.83%
- 50-day average
- 1.30
- Volume
- 196.91K
- Avg volume
- 120.35K
- Open
- 0.95
- Previous close
- 0.9538
- Day's range
- 0.8651 – 0.9651
- 52-week range
- 0.769 – 1.84
- Beta
- 0.29
5D -0.0306 (-3.26%)
Key statistics
- 200-day average
- 28.72
- Enterprise value
- -15.92M
- Free cash flow
- -12.94M
- Total cash
- 19.23M
- Total debt
- 1.32M
- Return on equity
- -121.82%
- Short % of float
- 12.70%
Fundamental scorecard
2 of 25 checks passed on ALLR’s reported financials
2of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -7.71 | — | — |
| Aug 5, 2024 | Jun 1, 2024 | 0.00 | -3.30 | — | — |
| Aug 5, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -664.86 | — | — |
| Mar 8, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- allarity.com
News
Allarity Therapeutics Confirms Expanded Eligibility For Ongoing Phase 2 Trial In Advanced Ovarian Cancer
Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts Allarity Therapeutics Q3 EPS $(0.39) Misses $(0.21) Estimate, Sales $5.000K
Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance Allarity Therapeutics Settles $4.9M Novartis Liability For $1M Payment
Allarity Therapeutics Terminates $6M Equity Purchase Agreement With Tumim Stone Capital To Pursue Alternative Financing; Says No Early Termination Penalty Is Payable
Allarity Therapeutics Receives First Contract For Its Development, Validation And Related Laboratory Services From Undisclosed European Biotech Firm
Your note
Sign in to keep a note on ALLR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.42% | 18,452 | 18.73K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 3,403 | 3.45K | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 11 | 11 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.16% | 7,192 | 7.30K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 2,601 | 2.64K | Oct 30, 2024 |
